The Movember Foundation's GAP3 cohort

a profile of the largest global prostate cancer active surveillance database to date

Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objectives: The Movember Foundation launched the Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative to create a global consensus on the selection and monitoring of men with low-risk prostate cancer (PCa) on active surveillance (AS). The aim of this study is to present data on inclusion and follow-up for AS in this unique global AS database. Patients and Methods: Between 2014 and 2016, the database was created by combining patient data from 25 established AS cohorts worldwide (USA, Canada, Australasia, UK and Europe). Data on a total of 15 101 patients were included. Descriptive statistics were used to report patients' clinical and demographic characteristics at the time of PCa diagnosis, clinical follow-up, discontinuation of AS and subsequent treatment. Cumulative incidence curves were used to report discontinuation rates over time. Results: At diagnosis, the median (interquartile range [IQR]) patient age was 65 (60–70) years and the median prostate-specific antigen level was 5.4 (4.0–7.3) ng/mL. Most patients had clinical stage T1 disease (71.8%), a biopsy Gleason score of 6 (88.8%) and one tumour-positive biopsy core (60.3%). Patients on AS had a median follow-up time of 2.2 (1.0–5.0) years. After 5, 10 and 15 years of follow-up, respectively, 58%, 39% and 23% of patients were still on AS. The current version of GAP3 has limited data on magnetic resonance imaging (MRI), quality of life and genomic testing. Conclusions: GAP3 is the largest worldwide collaboration integrating patient data from men with PCa on AS. The results will allow individual patients and clinicians to have greater confidence in the personalized decision to either delay or proceed with active treatment. Longer follow-up and the evaluation of MRI, new genomic markers and patient-related outcomes will result in even more valuable data and eventually in better patient outcomes.

Original languageEnglish
Pages (from-to)737-744
Number of pages8
JournalBJU International
Volume121
Issue number5
DOIs
Publication statusPublished - 2018 May 1

Fingerprint

Prostatic Neoplasms
Databases
Magnetic Resonance Imaging
Australasia
Biopsy
Neoplasm Grading
Prostate-Specific Antigen
Canada
Quality of Life
Demography
Incidence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium (2018). The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date. BJU International, 121(5), 737-744. https://doi.org/10.1111/bju.14106
Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium. / The Movember Foundation's GAP3 cohort : a profile of the largest global prostate cancer active surveillance database to date. In: BJU International. 2018 ; Vol. 121, No. 5. pp. 737-744.
@article{f0881fd6f3064091bf4f2bbaf9af2e79,
title = "The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date",
abstract = "Objectives: The Movember Foundation launched the Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative to create a global consensus on the selection and monitoring of men with low-risk prostate cancer (PCa) on active surveillance (AS). The aim of this study is to present data on inclusion and follow-up for AS in this unique global AS database. Patients and Methods: Between 2014 and 2016, the database was created by combining patient data from 25 established AS cohorts worldwide (USA, Canada, Australasia, UK and Europe). Data on a total of 15 101 patients were included. Descriptive statistics were used to report patients' clinical and demographic characteristics at the time of PCa diagnosis, clinical follow-up, discontinuation of AS and subsequent treatment. Cumulative incidence curves were used to report discontinuation rates over time. Results: At diagnosis, the median (interquartile range [IQR]) patient age was 65 (60–70) years and the median prostate-specific antigen level was 5.4 (4.0–7.3) ng/mL. Most patients had clinical stage T1 disease (71.8{\%}), a biopsy Gleason score of 6 (88.8{\%}) and one tumour-positive biopsy core (60.3{\%}). Patients on AS had a median follow-up time of 2.2 (1.0–5.0) years. After 5, 10 and 15 years of follow-up, respectively, 58{\%}, 39{\%} and 23{\%} of patients were still on AS. The current version of GAP3 has limited data on magnetic resonance imaging (MRI), quality of life and genomic testing. Conclusions: GAP3 is the largest worldwide collaboration integrating patient data from men with PCa on AS. The results will allow individual patients and clinicians to have greater confidence in the personalized decision to either delay or proceed with active treatment. Longer follow-up and the evaluation of MRI, new genomic markers and patient-related outcomes will result in even more valuable data and eventually in better patient outcomes.",
author = "{Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium} and Bruinsma, {Sophie M.} and Liying Zhang and Roobol, {Monique J.} and Bangma, {Chris H.} and Steyerberg, {Ewout W.} and Daan Nieboer and {Van Hemelrijck}, Mieke and Bruce Trock and Behfar Ehdaie and Peter Carroll and Christopher Filson and Jeri Kim and Todd Morgan and Laurence Klotz and Tom Pickles and Eric Hyndman and Moore, {Caroline M.} and Vincent Gnanapragasam and Prokar Dasgupta and Arnauld Villers and Antti Rannikko and Riccardo Valdagni and Antoinette Perry and Jonas Hugosson and Jose Rubio-Briones and Anders Bjartell and Lukas Hefermehl and {Lui Shiong}, Lee and Mark Frydenberg and Yoshiyuki Kakehi and Byungha Chung and {van der Kwast}, Theo and Henk Obbink and {van der Linden}, Wim and Tim Hulsen and {de Jonge}, Cees and Mike Kattan and Ji Xinge and Kenneth Muir and Artitaya Lophatananon and Michael Fahey and Wei Guo and Tanya Milan and Nicole Benfante and Janet Cowan and Dattatraya Patil and Rachel Sanford and Kim, {Tae Kyung} and Alexandre Mamedov and Vincent LaPointe",
year = "2018",
month = "5",
day = "1",
doi = "10.1111/bju.14106",
language = "English",
volume = "121",
pages = "737--744",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "5",

}

Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium 2018, 'The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date', BJU International, vol. 121, no. 5, pp. 737-744. https://doi.org/10.1111/bju.14106

The Movember Foundation's GAP3 cohort : a profile of the largest global prostate cancer active surveillance database to date. / Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium.

In: BJU International, Vol. 121, No. 5, 01.05.2018, p. 737-744.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The Movember Foundation's GAP3 cohort

T2 - a profile of the largest global prostate cancer active surveillance database to date

AU - Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium

AU - Bruinsma, Sophie M.

AU - Zhang, Liying

AU - Roobol, Monique J.

AU - Bangma, Chris H.

AU - Steyerberg, Ewout W.

AU - Nieboer, Daan

AU - Van Hemelrijck, Mieke

AU - Trock, Bruce

AU - Ehdaie, Behfar

AU - Carroll, Peter

AU - Filson, Christopher

AU - Kim, Jeri

AU - Morgan, Todd

AU - Klotz, Laurence

AU - Pickles, Tom

AU - Hyndman, Eric

AU - Moore, Caroline M.

AU - Gnanapragasam, Vincent

AU - Dasgupta, Prokar

AU - Villers, Arnauld

AU - Rannikko, Antti

AU - Valdagni, Riccardo

AU - Perry, Antoinette

AU - Hugosson, Jonas

AU - Rubio-Briones, Jose

AU - Bjartell, Anders

AU - Hefermehl, Lukas

AU - Lui Shiong, Lee

AU - Frydenberg, Mark

AU - Kakehi, Yoshiyuki

AU - Chung, Byungha

AU - van der Kwast, Theo

AU - Obbink, Henk

AU - van der Linden, Wim

AU - Hulsen, Tim

AU - de Jonge, Cees

AU - Kattan, Mike

AU - Xinge, Ji

AU - Muir, Kenneth

AU - Lophatananon, Artitaya

AU - Fahey, Michael

AU - Guo, Wei

AU - Milan, Tanya

AU - Benfante, Nicole

AU - Cowan, Janet

AU - Patil, Dattatraya

AU - Sanford, Rachel

AU - Kim, Tae Kyung

AU - Mamedov, Alexandre

AU - LaPointe, Vincent

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Objectives: The Movember Foundation launched the Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative to create a global consensus on the selection and monitoring of men with low-risk prostate cancer (PCa) on active surveillance (AS). The aim of this study is to present data on inclusion and follow-up for AS in this unique global AS database. Patients and Methods: Between 2014 and 2016, the database was created by combining patient data from 25 established AS cohorts worldwide (USA, Canada, Australasia, UK and Europe). Data on a total of 15 101 patients were included. Descriptive statistics were used to report patients' clinical and demographic characteristics at the time of PCa diagnosis, clinical follow-up, discontinuation of AS and subsequent treatment. Cumulative incidence curves were used to report discontinuation rates over time. Results: At diagnosis, the median (interquartile range [IQR]) patient age was 65 (60–70) years and the median prostate-specific antigen level was 5.4 (4.0–7.3) ng/mL. Most patients had clinical stage T1 disease (71.8%), a biopsy Gleason score of 6 (88.8%) and one tumour-positive biopsy core (60.3%). Patients on AS had a median follow-up time of 2.2 (1.0–5.0) years. After 5, 10 and 15 years of follow-up, respectively, 58%, 39% and 23% of patients were still on AS. The current version of GAP3 has limited data on magnetic resonance imaging (MRI), quality of life and genomic testing. Conclusions: GAP3 is the largest worldwide collaboration integrating patient data from men with PCa on AS. The results will allow individual patients and clinicians to have greater confidence in the personalized decision to either delay or proceed with active treatment. Longer follow-up and the evaluation of MRI, new genomic markers and patient-related outcomes will result in even more valuable data and eventually in better patient outcomes.

AB - Objectives: The Movember Foundation launched the Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative to create a global consensus on the selection and monitoring of men with low-risk prostate cancer (PCa) on active surveillance (AS). The aim of this study is to present data on inclusion and follow-up for AS in this unique global AS database. Patients and Methods: Between 2014 and 2016, the database was created by combining patient data from 25 established AS cohorts worldwide (USA, Canada, Australasia, UK and Europe). Data on a total of 15 101 patients were included. Descriptive statistics were used to report patients' clinical and demographic characteristics at the time of PCa diagnosis, clinical follow-up, discontinuation of AS and subsequent treatment. Cumulative incidence curves were used to report discontinuation rates over time. Results: At diagnosis, the median (interquartile range [IQR]) patient age was 65 (60–70) years and the median prostate-specific antigen level was 5.4 (4.0–7.3) ng/mL. Most patients had clinical stage T1 disease (71.8%), a biopsy Gleason score of 6 (88.8%) and one tumour-positive biopsy core (60.3%). Patients on AS had a median follow-up time of 2.2 (1.0–5.0) years. After 5, 10 and 15 years of follow-up, respectively, 58%, 39% and 23% of patients were still on AS. The current version of GAP3 has limited data on magnetic resonance imaging (MRI), quality of life and genomic testing. Conclusions: GAP3 is the largest worldwide collaboration integrating patient data from men with PCa on AS. The results will allow individual patients and clinicians to have greater confidence in the personalized decision to either delay or proceed with active treatment. Longer follow-up and the evaluation of MRI, new genomic markers and patient-related outcomes will result in even more valuable data and eventually in better patient outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85045912820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045912820&partnerID=8YFLogxK

U2 - 10.1111/bju.14106

DO - 10.1111/bju.14106

M3 - Article

VL - 121

SP - 737

EP - 744

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 5

ER -

Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium. The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date. BJU International. 2018 May 1;121(5):737-744. https://doi.org/10.1111/bju.14106